BiotechTube

Placebo DONQ52 + DONQ52

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Dec 16, 2025 → Dec 15, 2027

NCT ID
NCT07239336

About Placebo DONQ52 + DONQ52

Placebo DONQ52 + DONQ52 is a phase 2 stage product being developed by Chugai Pharmaceutical for Celiac Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07239336. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07239336Phase 2Recruiting

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
DONQ52 + PlaceboChugai PharmaceuticalPhase 1
29
Placebo + RO5459072RochePhase 1
29
CCX282-B + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
Rifaximin + PlaceboBausch HealthPre-clinical
20
LatiglutenaseAllergy TherapeuticsPhase 2
21
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26